Overweight and ObesityNCT07551193
Evaluating Weight Loss Outcomes in Patients With Overweight or Obesity
An observational study of Overweight and Obesity, run by Aldafter Medical Center, Bahrain at 1 site in Bahrain.
Trial summary
The goal of this observational study is to evaluate weight loss outcomes in adults with overweight or obesity using weight management medications. The main questions it aims to answer are: (1) How much weight do patients lose after 12 months? (2) Do blood sugar and cholesterol levels improve? (3) How safe and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overweight and Obesity
- How many people
- 300 participants
- Where
- 1 siteBahrain
- Study dates
- 25 Oct 2025to 30 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) with overweight or obesity (BMI ≥25) who received weight management medications. Patients must have continuous insurance enrollment for 12 months before and after treatment initiation, and weight measurements at both baseline and 12 months.
Who may be able to join
- Age: Adults aged 18 years or older.
- Body Mass Index (BMI): Patients classified as overweight (BMI 25-29.9 kg/m²) or obese (BMI ≥30 kg/m²).
- Medication: At least one pharmacy claim for any approved weight management medication
- Continuous Enrollment: Patients must have continuous enrollment in medical and pharmacy insurance for 1 year prior to the index date (date of treatment initiation) and 1 year afterward.
- -
Who cannot join
- Type 1 Diabetes: Patients with a diagnosis of type 1 diabetes.
- Non-Compliance: Evidence of non-compliance with treatment (e.g., gaps in therapy greater than 30 days).
- Bariatric Surgery: Patients who have undergone bariatric surgery in the past 5 years.
- Serious Comorbidities: Presence of serious medical conditions that may confound weight loss outcomes (e.g., uncontrolled psychiatric disorders, cancer).
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this observational study is to evaluate weight loss outcomes in adults with overweight or obesity using weight management medications. The main questions it aims to answer are: (1) How much weight do patients lose after 12 months? (2) Do blood sugar and cholesterol levels improve? (3) How safe and tolerable are these medications? This is a retrospective study using existing medical records and pharmacy claims. Participants will not be asked to do anything new; all data will be collected from routine clinical care.
Read the detailed description
The goal of this observational study is to learn how much weight adults with overweight or obesity lose after taking weight management for 12 months. The study also aims to learn whether these medications improve blood sugar and cholesterol levels, and how safe and tolerable they are.
The main questions it aims to answer are:
How much weight (in kilograms and percentage) do patients lose after 12 months of treatment? Do patients' fasting blood sugar, HbA1c, and cholesterol levels improve after 12 months? What side effects or treatment discontinuations occur in routine clinical practice? Researchers will compare weight loss outcomes among different patient groups based on age, sex, baseline BMI, and the specific medication used.
This is a retrospective study, meaning participants will not be asked to do anything new. Researchers will collect information from existing medical records and pharmacy claims at Aldafter Medical Center (ADMC) in Bahrain, including weight measurements, lab results, and medication histories from routine clinical care.
- Conditions
- Overweight and Obesity
- Keywords
- obesity
- Medical subject headings
- Overweight, Obesity
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute Weight Change
Absolute weight change (kg) from baseline to 12 months
Measured: Baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start25 Oct 2025
- Primary completion25 Jun 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight and ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aldafter Medical Center, Bahrain
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Huda Omran, Aldafter Medical Center, Bahrain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07551193
- Sponsor's protocol ID
- ADMC-WL-2025-01
- Status last verified
- Sep 2025
- First submitted
- 20 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared with other researchers. Only de-identified aggregate results will be published.
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Weight Loss Outcomes in Patients With Overweight or Obesity
- ClinicalTrials.gov ID
- NCT07551193
- Acronym / sponsor ID
- ADMC-WL-2025-01
- Conditions
- Overweight and Obesity
- Keywords
- obesity
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Aldafter Medical Center, BahrainUniversity, hospital or other
- Study start
- 25 Oct 2025 (actual)
- Primary completion
- 25 Jun 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate weight loss outcomes in adults with overweight or obesity using weight management medications. The main questions it aims to answer are: (1) How much weight do patients lose after 12 months? (2) Do blood sugar and cholesterol levels improve? (3) How safe and tolerable are these medications? This is a retrospective study using existing medical records and pharmacy claims. Participants will not be asked to do anything new; all data will be collected from routine clinical care.
Detailed description
The goal of this observational study is to learn how much weight adults with overweight or obesity lose after taking weight management for 12 months. The study also aims to learn whether these medications improve blood sugar and cholesterol levels, and how safe and tolerable they are.
The main questions it aims to answer are:
How much weight (in kilograms and percentage) do patients lose after 12 months of treatment? Do patients' fasting blood sugar, HbA1c, and cholesterol levels improve after 12 months? What side effects or treatment discontinuations occur in routine clinical practice? Researchers will compare weight loss outcomes among different patient groups based on age, sex, baseline BMI, and the specific medication used.
This is a retrospective study, meaning participants will not be asked to do anything new. Researchers will collect information from existing medical records and pharmacy claims at Aldafter Medical Center (ADMC) in Bahrain, including weight measurements, lab results, and medication histories from routine clinical care.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) with overweight or obesity (BMI ≥25) who received weight management medications. Patients must have continuous insurance enrollment for 12 months before and after treatment initiation, and weight measurements at both baseline and 12 months.
Key inclusion criteria (5 listed)
- Age: Adults aged 18 years or older.
- Body Mass Index (BMI): Patients classified as overweight (BMI 25-29.9 kg/m²) or obese (BMI ≥30 kg/m²).
- Medication: At least one pharmacy claim for any approved weight management medication
- Continuous Enrollment: Patients must have continuous enrollment in medical and pharmacy insurance for 1 year prior to the index date (date of treatment initiation) and 1 year afterward.
- -
Key exclusion criteria (4 listed)
- Type 1 Diabetes: Patients with a diagnosis of type 1 diabetes.
- Non-Compliance: Evidence of non-compliance with treatment (e.g., gaps in therapy greater than 30 days).
- Bariatric Surgery: Patients who have undergone bariatric surgery in the past 5 years.
- Serious Comorbidities: Presence of serious medical conditions that may confound weight loss outcomes (e.g., uncontrolled psychiatric disorders, cancer).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Absolute Weight Change
Time frame: Baseline to 12 months
Absolute weight change (kg) from baseline to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared with other researchers. Only de-identified aggregate results will be published.
Related trials for Overweight and Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overweight and Obesity, run by Aldafter Medical Center, Bahrain at 1 site in Bahrain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bahrain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute Weight Change (time frame: Baseline to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.